In particular, by applying gene and protein profiling on primary AML BM samples, the identified IFN-dominant immune subtypes, obtained as the sum of IFN-γ signaling, inflammatory chemokine, and immune-related scores, predicts shorter overall survival, chemotherapy resistance, and the response of primary refractory/relapsed AML to flotetuzumab immunotherapy, which activates and expands residual T cells mediating AML cell eradication [188]. This evidence concerns the gene IFNG and acute myeloid leukemia.